Aspirin therapy: An attempt to explain the events of prothrombotic complications after treatment discontinuation

Summary

Aspirin remains the most widely used drug for prevention of vascular events. Recent observational epidemiological evidence has raised the concern that aspirin withdrawal for treatment non-compliance, surgery or side effects can carry an increased thrombotic risk. The delay to the thrombotic event was between 7 to 30 days in most reports and most frequently 7 to 10 days. The mechanism underlying this effect remains poorly understood. Using an in vivo model of laser-induced thrombosis, aspirin injected in one single dose of 100 mg/kg bw has also shown a prothrombotic activity in the rat 8 to 10 days after injection in the normal rat. The hypothesis was made that minimal concentrations of aspirin or ultra-low dose aspirin (ULDA) could induce this effect. ULDA showed prothrombotic properties in the same model of induced thrombosis that were very similar to those described after aspirin withdrawal, but the effect was observed only one hour after aspirin administration. This prothrombotic effect of ULDA is very similar to the effect observed after COX 2 selective inhibition with NS 398. The administration of both the selective COX 2 inhibitor and ULDA did not produce further changes. High-dose ASA counterbalances the lack of COX 2 with an antithrombotic effect. No effect of residual ASA was observed in COX 2 -/- mice, thus confirming the existence of a COX 2 inhibition pathway. COX 2 inhibition produced by residual ASA is the probable cause of ischaemic accidents and drug-eluting stents thrombosis a few days after ASA withdrawal.

Keywords

Aspirin withdrawal - thrombosis - COX inhibition - “knock-out” mice

• References

• 1 Chen ZM, Jiang LX, Chen YP. et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 2 Bhatt DL, Fox KA, Hacke W. et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
• 3 Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischaemic stroke. Neurology 2004; 62: 1187-1189.
• 4 Maulaz AB, Bezerra DC, Michel P. et al. Effect of discontinuing aspirin therapy on the risk of brain ischaemic stroke. Arch Neurol 2005; 62: 1217-1220.
• 5 Armstrong MJ, Schneck MJ, Biller J. Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients. Neurol Clin 2006; 24: 607-630.
• 6 Fischer LM, Schlienger RG, Matter CM. et al. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004; 164: 2472-2476.
• 7 Ferrari E, Benhamou M, Cerboni P. et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459.
• 8 Burger W, Chemnitius JM, Kneissl GD. et al. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257: 399-414.
• 9 Collet JP, Montalescot G, Blanchet B. et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-2367.
• 10 Ho PM, Spertus JA, Masoudi FA. et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
• 11 Biondi-Zoccai GG, Lotrionte M, Agostoni P. et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-2674.
• 12 Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257-258.
• 13 Albaladejo P, Geeraerts T, Francis F. et al. Aspirin withdrawal and acute lower limb ischaemia. Anesth Analg 2004; 99: 440-443.
• 14 Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 157-160.
• 15 Vesvres MH, Doutremepuich F, Lalanne MC. et al. Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. Haemostasis 1993; 23: 8-12.
• 16 Doutremepuich C, Aguejouf O, Belon P. Effects of ultra-low-dose aspirin on embolization in a model of laser-induced thrombus formation. Semin Thromb He-most 1996; 22 (Suppl. 01) 67-70.
• 17 Aguejouf O, Belougne-Malfatti E, Doutremepuich F. et al. Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res 1998; 89: 123-127.
• 18 Smith CJ, Zhang Y, Koboldt CM. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998; 95: 13313-13318.
• 19 Brenneis C, Maier TJ, Schmidt R. et al. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J 2006; 20: 1352-1360.
• 20 Arnett J, Chow J, Ives D. et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209: 130-139.
• 21 Masferrer JL, Zweifel BS, Manning PT. et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
• 22 Ohnson JL, Wimsatt J, Buckel SD. et al. Purification and characterization of pros-taglandin H synthase-2 from sheep placental cotyledons. Arch Biochem Biophys 1995; 324: 26-34.
• 23 Doutremepuich C, Aguejouf O, Eizayaga F. et al. Reverse effect of aspirin: is the pro-thrombotic effect after aspirin discontinuation mediated by COX 2 blockade?. Circulation 2006; 114: II_73.
• 24 Aguejouf O, Eizayaga F, Desplat V. et al. Reverse effect of Aspirin: Is the prothrombotic affect of Aspirin discontinuation mediated by COX 2 inhibition?. Pathophysiol Haemost Thromb 2007; -2008 36: 40-44.
• 25 Langenbach R, Morham SG, Tiano HF. et al. Prostaglandin Synthase 1 Gene Disruption in Mice Reduces Arachidonic Acid-Induced Inflammation and Indomethacin-Induced Gastric Ulceration. Cell 1995; 83: 483-492.
• 26 Morham SG, Langenbach R, Loftin CD. et al. Prostaglandin Synthase 2 Gene Disruption Causes Severe Renal Pathology in the Mouse. Cell 1995; 83: 472-482.
• 27 Skill NJ, Theodorakis NG, Wang YN. et al. Role of cycloooxygenase isoforms in prostacycline biosynthesis and murine prehepatic portal hypertension. Am J Physiol Gastrointest Liver Physiol 2008; 295: G953-964.
• 28 Taubert D, Berkels R, Grosser N. et al. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143: 159-165.
• 29 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
• 30 Blais N, Pharand C, Lordkipanidzé M. et al. Response to aspirin in healthy individuals – Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2. Thromb Haemost 2009; 102: 404-411.
• 31 Wu KK. Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thromb Res 2003; 110: 273-276.